HRP20230504T1 - Antagonisti aktivin-actrii i upotreba u liječenju mijelodisplastičnog sindroma - Google Patents
Antagonisti aktivin-actrii i upotreba u liječenju mijelodisplastičnog sindroma Download PDFInfo
- Publication number
- HRP20230504T1 HRP20230504T1 HRP20230504TT HRP20230504T HRP20230504T1 HR P20230504 T1 HRP20230504 T1 HR P20230504T1 HR P20230504T T HRP20230504T T HR P20230504TT HR P20230504 T HRP20230504 T HR P20230504T HR P20230504 T1 HRP20230504 T1 HR P20230504T1
- Authority
- HR
- Croatia
- Prior art keywords
- signaling inhibitor
- subject
- actrii signaling
- use according
- months
- Prior art date
Links
- 201000003793 Myelodysplastic syndrome Diseases 0.000 title claims 3
- 239000005557 antagonist Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 claims 41
- 230000011664 signaling Effects 0.000 claims 41
- 210000003924 normoblast Anatomy 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 102000001554 Hemoglobins Human genes 0.000 claims 11
- 108010054147 Hemoglobins Proteins 0.000 claims 11
- 230000007774 longterm Effects 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims 2
- 210000003743 erythrocyte Anatomy 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 102000005606 Activins Human genes 0.000 claims 1
- 108010059616 Activins Proteins 0.000 claims 1
- 239000000488 activin Substances 0.000 claims 1
- 238000004820 blood count Methods 0.000 claims 1
- 238000005534 hematocrit Methods 0.000 claims 1
- 238000010606 normalization Methods 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Ecology (AREA)
- General Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (18)
1. Inhibitor signalizacije receptora aktivina tipa II (ActRII) za upotrebu u postupku liječenja mijelodisplastičnih sindroma (MDS) kod subjekta, pri čemu postupak obuhvaća:
(a) određivanje postotka eritroblasta kod subjekta koji su prstenasti sideroblasti; i
(b) davanje subjektu farmaceutski učinkovite doze inhibitora signalizacije ActRII između 0,1 mg/kg i 2,0 mg/kg, ako je najmanje 15%, 16%, 17%, 18%, 19% ili 20% od eritroblasta kod subjekta prstenasti sideroblasti,
pri čemu je navedeni inhibitor signalizacije ActRII polipeptid koji sadrži:
(i) aminokiselinsku sekvencu koja je najmanje 90% identična sa SEQ ID NO:7;
(ii) aminokiselinsku sekvencu koja je najmanje 95% identična sa SEQ ID NO:7;
(iii) aminokiselinsku sekvencu koja je najmanje 98% identična sa SEQ ID NO:7;
(iv) aminokiselinsku sekvencu SEQ ID NO:7;
(v) aminokiselinsku sekvencu koja je najmanje 90% identična sa SEQ ID NO:25;
(vi) aminokiselinsku sekvencu koja je najmanje 95% identična sa SEQ ID NO:25;
(vii) aminokiselinsku sekvencu koja je najmanje 98% identična sa SEQ ID NO:25;
(viii) aminokiselinsku sekvencu SEQ ID NO:25; ili
(ix) fragment izvanstanične domene ActRIIB, pri čemu se fragment sastoji od aminokiselinske sekvence SEQ ID NO:23; poveznice; i Fc od IgG.
2. Inhibitor signalizacije ActRII za upotrebu prema zahtjevu 1, naznačen time što se postupkom postiže:
(a) dugoročno smanjenje postotka eritroblasta kod subjekta koji su prstenasti sideroblasti u usporedbi s početnim postotkom eritroblasta kod subjekta koji su prstenasti sideroblasti, pri čemu dugoročno smanjenje je smanjenje postotka eritroblasta koje se održava najmanje 1, 2, 3, 4, 5, 6, 12, 18 ili 24 mjeseca nakon razdoblja primjene inhibitora signalizacije ActRII; i/ili
(b) dugotrajno povećanje razine hemoglobina kod subjekta u usporedbi s početnom razinom hemoglobina kod subjekta, pri čemu je početna razina hemoglobina kod subjekta razina hemoglobina kod subjekta u vremenskom razdoblju prije davanja subjektu početne dozu inhibitora signalizacije ActRII; pri čemu dugoročno povećanje je povećanje razine hemoglobina koje se održava najmanje 3, 4, 5, 6, 12, 18 ili 24 mjeseca nakon vremenskog razdoblja primjene inhibitora signalizacije ActRII.
3. Inhibitor signalizacije ActRII za upotrebu prema zahtjevu 1 ili 2, naznačen time što se inhibitor signalizacije ActRII primjenjuje u kratkom vremenskom periodu, i pri čemu je kratki vremenski period 1, 2, 3, 4 ili 5 mjeseci.
4. Inhibitor signalizacije ActRII za upotrebu prema zahtjevu 1 ili 2, naznačen time što postupak nadalje obuhvaća:
(c) određivanje drugog postotka eritroblasta kod subjekta koji su prstenasti sideroblasti nakon određenog vremenskog razdoblja, izborno pri čemu je vremenski period 1, 2, 3, 4, 5 ili 6 mjeseci; i
(d) izborno davanje subjektu prilagođene doze inhibitora signalizacije ActRII.
5. Inhibitor signalizacije ActRII za upotrebu prema zahtjevu 1 ili 2, naznačen time što postupak nadalje obuhvaća:
(c) određivanje razine hemoglobina kod subjekta nakon što je subjektu primijenjen inhibitor signalizacije ActRII, izborno pri čemu se razina hemoglobina određuje unutar 6, 12, 18 i/ili 24 mjeseca nakon što je primijenjen inhibitor signalizacije ActRII; i
(d) prekid primjene inhibitora signalizacije ActRII subjektu, ako je razina hemoglobina kod subjekta najmanje 11 g/dL.
6. Inhibitor signalizacije ActRII za upotrebu prema zahtjevu 1, naznačen time što se postotak eritroblasta kod subjekta koji su prstenasti sideroblasti određuje unutar 1 dana, 2 dana, 3 dana, 4 dana, 5 dana, 6 dana, 1 tjedna, 2 tjedana, 3 tjedna, 4 tjedna, 5 tjedana, 6 tjedana, 7 tjedana, 8 tjedana, 3 mjeseca, 4 mjeseca, 5 mjeseci ili 6 mjeseci davanja subjektu farmaceutski učinkovite doze inhibitora signalizacije ActRII.
7. Inhibitor signalizacije ActRII za upotrebu prema zahtjevu 2, naznačen time što je dugoročno smanjenje postotka eritroblasta kod subjekta koji su prstenasti sideroblasti najmanje 1,5, 2,5, 5,0, 7,5 ili 10,0 puta ispod početnog postotka eritroblasta kod subjekta koji su prstenasti sideroblasti najmanje 6, 12, 18 ili 24 mjeseca nakon razdoblja primjene inhibitora signalizacije ActRII.
8. Inhibitor signalizacije ActRII za upotrebu prema zahtjevu 2, naznačen time što je dugotrajno povećanje razine hemoglobina kod subjekta razina hemoglobina između oko 11 g/dL i 18 g/dL kod subjekta tijekom najmanje 3, 4 , 5, 6, 12, 18 ili 24 mjeseca nakon razdoblja primjene inhibitora signalizacije ActRII.
9. Inhibitor signalizacije ActRII za upotrebu prema zahtjevu 3, naznačen time što
(i) prvi postotak eritroblasta koji su prstenasti sideroblasti kod subjekta kojemu je primijenjen inhibitor signalizacije ActRII tijekom kratkog vremenskog razdoblja smanjen je na manje od 10%, 9%, 8%, 7%, 6%, 5%, 4 %, 3%, 2% ili manje od 1% tijekom najmanje 6, 12, 18 ili 24 mjeseca nakon kratkog vremenskog razdoblja primjene inhibitora signalizacije ActRII; i/ili
(ii) razina hemoglobina kod subjekta kojem je primijenjen inhibitor signalizacije ActRII u kratkom vremenskom razdoblju je između oko 11 g/dL i 18 g/dL tijekom najmanje 3, 4, 5, 6, 12, 18 ili 24 mjeseca nakon razdoblja primjene inhibitora signalizacije ActRII.
10. Inhibitor signalizacije ActRII za upotrebu prema bilo kojem od zahtjeva 1 do 9, naznačen time što subjekt ima povećanu vjerojatnost postizanja normalizacije jednog ili više hematoloških parametara, ako je najmanje 15%, 16%, 17%, 18%, 19 % ili 20% eritroblasta kod subjekta, prstenasti sideroblasti u usporedbi sa subjektom koji ima najviše 15% eritroblasta koji su prstenasti sideroblasti.
11. Inhibitor signalizacije ActRII za upotrebu prema zahtjevu 10, naznačen time što je hematološki parametar razina hemoglobina, hematokrit, broj crvenih krvnih stanica ili postotak eritroblasta kod subjekta koji su prstenasti sideroblasti.
12. Inhibitor signalizacije ActRII za upotrebu prema bilo kojem od zahtjeva 1 do 11, naznačen time što kod subjekta nije potrebna transfuzija crvenih krvnih stanica najmanje 3, 4, 5, 6, 12, 18 ili 24 mjeseca nakon vremenskog razdoblja primjene inhibitora signalizacije ActRII.
13. Inhibitor signalizacije ActRII za upotrebu prema bilo kojem od zahtjeva 1 do 12, naznačen time što se inhibitor signalizacije ActRII primjenjuje:
(i) jednom svaka tri tjedna;
(ii) jednom svakih 28 dana; ili
(iii) jednom svaka 42 dana.
14. Inhibitor signalizacije ActRII za upotrebu prema bilo kojem od zahtjeva 1 do 13, naznačen time što se inhibitor signalizacije ActRII primjenjuje putem injekcije, po izboru pri čemu je injekcija potkožna.
15. Inhibitor signalizacije ActRII za upotrebu prema bilo kojem od zahtjeva 1 do 14, naznačen time što je inhibitor signalizacije ActRII polipeptid koji sadrži aminokiselinsku sekvencu SEQ ID NO:25.
16. Inhibitor signalizacije ActRII za upotrebu prema bilo kojem od zahtjeva 1 do 14, naznačen time što je inhibitor signalizacije ActRII polipeptid koji sadrži aminokiselinsku sekvencu SEQ ID NO:7.
17. Inhibitor signalizacije ActRII za upotrebu prema bilo kojem od zahtjeva 1 do 14, naznačen time što je inhibitor signalizacije ActRII polipeptid koji sadrži fragment izvanstanične domene od ActRIIB, pri čemu se fragment sadrži aminokiselinsku sekvencu SEQ ID NO:23; poveznicu; i Fc od IgG.
18. Inhibitor signalizacije ActRII za upotrebu prema bilo kojem od zahtjeva 1 do 17, pri čemu je subjekt čovjek.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462086977P | 2014-12-03 | 2014-12-03 | |
US201462088478P | 2014-12-05 | 2014-12-05 | |
US201562153872P | 2015-04-28 | 2015-04-28 | |
US201562173782P | 2015-06-10 | 2015-06-10 | |
US201562218728P | 2015-09-15 | 2015-09-15 | |
PCT/US2015/063595 WO2016090077A1 (en) | 2014-12-03 | 2015-12-03 | Activin-actrii antagonists and uses for treating anemia |
EP15865213.1A EP3227675B1 (en) | 2014-12-03 | 2015-12-03 | Activin-actrii antagonists and uses for treating myelodysplastic syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20230504T1 true HRP20230504T1 (hr) | 2023-09-15 |
Family
ID=56092426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20230504TT HRP20230504T1 (hr) | 2014-12-03 | 2015-12-03 | Antagonisti aktivin-actrii i upotreba u liječenju mijelodisplastičnog sindroma |
Country Status (24)
Country | Link |
---|---|
US (1) | US11471510B2 (hr) |
EP (2) | EP4233889A3 (hr) |
JP (2) | JP2018501307A (hr) |
KR (1) | KR102556991B1 (hr) |
CN (2) | CN114675039A (hr) |
AU (2) | AU2015358469B2 (hr) |
BR (1) | BR112017011722A2 (hr) |
CA (1) | CA2969572A1 (hr) |
CY (1) | CY1126033T1 (hr) |
DK (1) | DK3227675T3 (hr) |
ES (1) | ES2946160T3 (hr) |
FI (1) | FI3227675T3 (hr) |
HK (2) | HK1245397A1 (hr) |
HR (1) | HRP20230504T1 (hr) |
HU (1) | HUE062189T2 (hr) |
IL (1) | IL252631B2 (hr) |
LT (1) | LT3227675T (hr) |
MD (1) | MD4801C1 (hr) |
PL (1) | PL3227675T3 (hr) |
PT (1) | PT3227675T (hr) |
RS (1) | RS64214B1 (hr) |
SI (1) | SI3227675T1 (hr) |
TW (2) | TWI730949B (hr) |
WO (1) | WO2016090077A1 (hr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
EP3964224A1 (en) | 2012-11-02 | 2022-03-09 | Celgene Corporation | Activin-actrii antagonists and uses for use in treating renal disease |
MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
ES2946160T3 (es) | 2014-12-03 | 2023-07-13 | Celgene Corp | Antagonistas de activina-ActRII y usos para tratar síndrome mielodisplásico |
ES2856001T3 (es) | 2015-04-22 | 2021-09-27 | Biogen Ma Inc | Nuevas proteínas híbridas de bloqueo del ligando actriib para tratar enfermedades de atrofia muscular |
EP4190805A3 (en) | 2015-05-20 | 2023-08-16 | Celgene Corporation | In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps |
WO2017079591A2 (en) | 2015-11-04 | 2017-05-11 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
EP3380121B1 (en) | 2015-11-23 | 2023-12-20 | Acceleron Pharma Inc. | Actrii antagonist for use in treating eye disorders |
US10041044B2 (en) | 2016-07-29 | 2018-08-07 | Trustees Of Boston University | Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development |
AU2017357944A1 (en) | 2016-11-10 | 2019-06-20 | Keros Therapeutics, Inc. | Activin receptor type IIa variants and methods of use thereof |
EP3638243A4 (en) | 2017-06-14 | 2021-03-17 | Celgene Corporation | METHOD OF TREATMENT OF MYELOPROLIFERATIVE NEOPLASM ASSOCIATED MYELOFIBROSIS AND ANEMIA |
KR20200085832A (ko) | 2017-11-09 | 2020-07-15 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
EP3737406A4 (en) | 2018-01-12 | 2021-11-03 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE IIB VARIANTS AND THEIR METHODS OF USE |
EP3788065A4 (en) * | 2018-04-30 | 2022-01-19 | The Children's Hospital Of Philadelphia | METHOD OF IMPROVING ANEMIA THROUGH COMBINATION OF AGENTS |
JP2022509525A (ja) * | 2018-10-31 | 2022-01-20 | セルジーン コーポレイション | 環状鉄芽球が見られる対象における非常に低リスク、低リスクまたは中程度のリスクの骨髄異形成症候群による貧血の、アクチビン-actriiリガンドトラップを用いた治療 |
WO2021189006A1 (en) * | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iia variants |
EP4121088A4 (en) * | 2020-03-20 | 2024-07-03 | Keros Therapeutics Inc | METHODS OF USING ACTIVIN TYPE IIB RECEPTOR VARIANTS |
CN115427056A (zh) * | 2020-04-13 | 2022-12-02 | 细胞基因公司 | 使用actriib配体陷阱和菲卓替尼治疗贫血的方法 |
EP4240399A1 (en) * | 2020-11-06 | 2023-09-13 | Acceleron Pharma Inc. | Formulations comprising actrii polypeptide variants |
Family Cites Families (194)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0637520B2 (ja) | 1985-07-03 | 1994-05-18 | 味の素株式会社 | ポリペプチド |
JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
US4973577A (en) | 1986-04-04 | 1990-11-27 | The Salk Institute For Biological Studies | FSH-releasing peptides |
US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
WO1992004913A1 (en) | 1990-09-13 | 1992-04-02 | Children's Hospital Medical Center Of Northern California | Method for increasing red blood cell production by treatment with activin or activin-related peptides |
US5118667A (en) | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
US20050186593A1 (en) | 1991-05-10 | 2005-08-25 | The Salk Institute For Biological Studies | Cloning and recombinant production of CRF receptor(s) |
US6162896A (en) | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
JPH06500574A (ja) | 1991-05-10 | 1994-01-20 | ザ ソーク インスティテュート フォア バイオロジカル スタディーズ | アクチビン/TGF―βスーパーファミリーのレセプターのクローニングおよび組換えによる産生 |
US5885794A (en) | 1991-05-10 | 1999-03-23 | The Salk Institute For Biological Studies | Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily |
KR100255415B1 (ko) | 1991-06-25 | 2000-05-01 | 브루스 엠. 에이센 | 비엠피-9 조성물 |
US6287816B1 (en) | 1991-06-25 | 2001-09-11 | Genetics Institute, Inc. | BMP-9 compositions |
US6692925B1 (en) | 1992-11-17 | 2004-02-17 | Ludwig Institute For Cancer Research | Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use |
EP1475440A3 (en) | 1993-01-12 | 2004-11-17 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-3 |
CA2161807A1 (en) | 1993-05-12 | 1994-11-24 | Anthony J. Celeste | Bmp-10 compositions |
US5637480A (en) | 1993-05-12 | 1997-06-10 | Genetics Institute, Inc. | DNA molecules encoding bone morphogenetic protein-10 |
US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
US5831050A (en) | 1993-06-07 | 1998-11-03 | Creative Biomolecules, Inc. | Morphogen cell surface receptor |
ATE355369T1 (de) | 1993-10-14 | 2006-03-15 | Harvard College | Verfahren zur induzierung und zur erhaltung neuronalen zellen |
US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
US5658876A (en) | 1994-04-28 | 1997-08-19 | The General Hospital Corporation | Activin antagonists as novel contraceptives |
US5885574A (en) | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
US5760010A (en) | 1995-01-01 | 1998-06-02 | Klein; Ira | Method of treating liver disorders with a macrolide antibiotic |
US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
ATE352638T1 (de) | 1995-04-11 | 2007-02-15 | Gen Hospital Corp | REVERSE ßTWO-HYBRIDß-SYSTEME |
EP0771873A3 (en) | 1995-10-27 | 1998-03-04 | Takeda Chemical Industries, Ltd. | Neuronal cell-specific receptor protein |
GB9526131D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Recombinant chimeric receptors |
US20050244867A1 (en) | 1996-03-26 | 2005-11-03 | Human Genome Sciences, Inc. | Growth factor HTTER36 |
US6004780A (en) | 1996-03-26 | 1999-12-21 | Human Genome Sciences, Inc. | Growth factor HTTER36 |
PL189756B1 (pl) | 1996-10-25 | 2005-09-30 | Searle & Co | Polipeptyd ludzkiego agonisty receptora erytropoetyny (EPO), sposób jego wytwarzania i zastosowanie, cząsteczka kwasu nukleinowego, kompozycja, sposób selektywnego namnażania ex vivo erytroidalnych komórek progenitorowych |
US6605699B1 (en) | 1997-01-21 | 2003-08-12 | Human Genome Sciences, Inc. | Galectin-11 polypeptides |
US6231880B1 (en) | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
EP1007673B1 (en) | 1997-07-30 | 2008-12-17 | Emory University | Novel bone mineralization proteins, dna, vectors, expression systems |
US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
AU8666398A (en) | 1997-08-01 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Methods to identify growth differentiation factor (gdf) receptors |
US6696260B1 (en) | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
US6953662B2 (en) | 1997-08-29 | 2005-10-11 | Human Genome Sciences, Inc. | Follistatin-3 |
AU8921698A (en) | 1997-08-29 | 1999-03-16 | Human Genome Sciences, Inc. | Follistatin-3 |
US6696411B1 (en) | 1998-04-22 | 2004-02-24 | Cornell Research Foundation, Inc. | Canine erythropoietin gene and recombinant protein |
BR9913857A (pt) | 1998-09-17 | 2001-06-12 | Lilly Co Eli | Formulações de proteìna |
DE69934995T2 (de) | 1998-09-22 | 2007-11-22 | Long Yu | Für den menschlichen wachstums-differenzierungsfaktor kodierende sequenz und polypeptid, welches durch solche dna-sequenz kodiert wird und verfahren zur herstellung |
US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
US6548634B1 (en) | 1998-09-30 | 2003-04-15 | Chiron Corporation | Synthetic peptides having FGF receptor affinity |
US6777205B1 (en) | 1998-11-06 | 2004-08-17 | Sterrenbeld Biotechnologie North America, Inc. | Host cells expressing recombinant human erythropoietin |
US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
MXPA01007366A (es) | 1999-01-21 | 2002-06-04 | Metamorphix Inc | Inhibidores de factores de crecimiento y diferenciacion y usos de los mismos. |
CA2365449A1 (en) | 1999-04-19 | 2000-10-26 | Kyowa Hakko Kogyo Co., Ltd. | Inhibitor of the growth of androgen-independent tumor |
US6468543B1 (en) | 1999-05-03 | 2002-10-22 | Zymogenetics, Inc. | Methods for promoting growth of bone using ZVEGF4 |
CA2390292A1 (en) | 1999-11-12 | 2001-05-25 | Maxygen Holdings Ltd. | Interferon gamma conjugates |
WO2001043763A1 (en) | 1999-12-15 | 2001-06-21 | Research Development Foundation | Betaglycan as an inhibin receptor and uses thereof |
JP4487376B2 (ja) | 2000-03-31 | 2010-06-23 | 味の素株式会社 | 腎疾患治療剤 |
US6627424B1 (en) | 2000-05-26 | 2003-09-30 | Mj Bioworks, Inc. | Nucleic acid modifying enzymes |
AU2001269709A1 (en) | 2000-07-19 | 2002-02-05 | Eli Lilly And Company | Nucleic acids, vectors, host cells, polypeptides, and uses thereof |
US6632180B1 (en) | 2000-09-07 | 2003-10-14 | John H. Laragh | Method for evaluating and treating hypertension |
DE10045591A1 (de) | 2000-09-15 | 2002-04-04 | Klaus Pfizenmaier | Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine) |
JP2004526419A (ja) | 2000-10-16 | 2004-09-02 | フィロス インク. | 抗体模倣物および他の結合タンパク質のためのタンパク質骨格 |
US7087224B2 (en) | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
WO2002040501A2 (en) | 2000-11-20 | 2002-05-23 | The Board Of Trustees Of The University Of Illinois | Membrane scaffold proteins |
EP1370287A2 (en) | 2000-12-01 | 2003-12-17 | Wyeth | Method and composition for modulating bone growth |
US20030082233A1 (en) | 2000-12-01 | 2003-05-01 | Lyons Karen M. | Method and composition for modulating bone growth |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
US20040132675A1 (en) | 2002-02-08 | 2004-07-08 | Calvin Kuo | Method for treating cancer and increasing hematocrit levels |
US7294472B2 (en) | 2001-03-14 | 2007-11-13 | Caden Biosciences | Method for identifying modulators of G protein coupled receptor signaling |
WO2002074340A1 (fr) | 2001-03-16 | 2002-09-26 | Takeda Chemical Industries, Ltd. | Procede de fabrication d'une preparation a liberation continue |
US20030082630A1 (en) | 2001-04-26 | 2003-05-01 | Maxygen, Inc. | Combinatorial libraries of monomer domains |
KR20040030628A (ko) | 2001-05-24 | 2004-04-09 | 지모제넥틱스, 인코포레이티드 | Taci-면역글로불린 융합 단백질 |
EP1390497A2 (en) | 2001-05-25 | 2004-02-25 | Genset | Human cdnas and proteins and uses thereof |
AUPR638101A0 (en) | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
US6855344B2 (en) | 2001-07-17 | 2005-02-15 | Integrated Chinese Medicine Holdings, Ltd. | Compositions and methods for prostate and kidney health and disorders, an herbal preparation |
ATE448481T1 (de) | 2001-07-17 | 2009-11-15 | Teijin Ltd | Selektionsverfahren für eine durch das austesten einer ppard aktivierenden wirkung charakterisierten substanz und arzneistoff |
KR100453877B1 (ko) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
US6784154B2 (en) | 2001-11-01 | 2004-08-31 | University Of Utah Research Foundation | Method of use of erythropoietin to treat ischemic acute renal failure |
US20030144203A1 (en) | 2001-12-19 | 2003-07-31 | Voyager Pharmaceutical Corporation | Methods for slowing senescence and treating and preventing diseases associated with senescence |
US6998118B2 (en) | 2001-12-21 | 2006-02-14 | The Salk Institute For Biological Studies | Targeted retrograde gene delivery for neuronal protection |
WO2003068801A2 (en) | 2002-02-11 | 2003-08-21 | Genentech, Inc. | Antibody variants with faster antigen association rates |
CA2476887A1 (en) | 2002-02-21 | 2003-09-04 | Wyeth | Gasp1:a follistatin domain containing protein |
US20030219846A1 (en) | 2002-02-28 | 2003-11-27 | Pfizer Inc. | Assay for activity of the ActRIIB kinase |
WO2003087162A2 (en) | 2002-04-18 | 2003-10-23 | Mtm Laboratories Ag | Neopeptides and methods useful for detection and treatment of cancer |
BR0313729A (pt) | 2002-08-16 | 2005-06-21 | Wyeth Corp | Elemento respondente a estrogênio bmp-2 e métodos de uso do mesmo |
BR0315316A (pt) | 2002-10-15 | 2005-08-16 | Celgene Corp | Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit |
AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
AU2002953327A0 (en) | 2002-12-12 | 2003-01-09 | Monash University | Methods of diagnosing prognosing and treating activin associated diseases and conditions |
AU2004210193B2 (en) | 2003-02-07 | 2007-07-12 | Prometic Pharma Smt Limited | Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis |
WO2004086953A2 (en) | 2003-03-26 | 2004-10-14 | The Board Of Trustees Of The University Of Arkansas | Method for diagnosis and treatment of bone turnover |
US20070184052A1 (en) | 2003-05-09 | 2007-08-09 | Lin Herbert Y | Soluble tgf-b type III receptor fusion proteins |
UA85055C2 (ru) | 2003-06-02 | 2008-12-25 | Уайт | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний |
JP4688802B2 (ja) | 2003-06-16 | 2011-05-25 | セルテック アール アンド ディー, インコーポレイテッド | 骨の鉱化作用を増大させるためのスクレロスチンに特異的な抗体および方法 |
US7611465B2 (en) | 2003-07-15 | 2009-11-03 | Board Of Regents, The University Of Texas System | Rapid and accurate detection of bone quality using ultrasound critical angle reflectometry |
WO2005009460A2 (en) | 2003-07-25 | 2005-02-03 | Medexis, S.A. | Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer |
DE10335211A1 (de) | 2003-08-01 | 2005-02-17 | Robert Bosch Gmbh | Kraftstoff-Einspritzvorrichtung für eine Brennkraftmaschine |
US20070135336A1 (en) | 2003-09-15 | 2007-06-14 | De Kretser David | Follistatin isoforms and uses thereof |
US8895540B2 (en) | 2003-11-26 | 2014-11-25 | DePuy Synthes Products, LLC | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
WO2005070967A2 (en) | 2004-01-22 | 2005-08-04 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
US20050197292A1 (en) | 2004-01-30 | 2005-09-08 | Glennda Smithson | Compositions and methods for treating T-cell mediated pathological conditions |
WO2005094871A2 (en) | 2004-03-26 | 2005-10-13 | Acceleron Pharma Inc. | Bmp-3 propeptides and related methods |
CA2561809A1 (en) | 2004-03-31 | 2005-10-20 | Xencor, Inc. | Bmp-7 variants with improved properties |
WO2005113590A2 (en) | 2004-05-12 | 2005-12-01 | Acceleron Pharma Inc. | Bmp10 propeptides and related methods |
WO2006002387A2 (en) | 2004-06-24 | 2006-01-05 | Acceleron Pharma Inc. | Gdf3 propeptides and related methods |
EP2314617B1 (en) | 2004-07-23 | 2015-06-24 | Acceleron Pharma Inc. | ActRII receptor polypeptides |
US20060034831A1 (en) | 2004-08-12 | 2006-02-16 | Wyeth | Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors |
WO2006039400A2 (en) | 2004-09-29 | 2006-04-13 | Mount Sinai School Of Medicine Of New York University | Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis |
US7879569B2 (en) * | 2004-11-09 | 2011-02-01 | The Trustees Of The University Of Pennsylvania | Methods for diagnosis of myelodysplastic syndromes (MDS) |
US20060234299A1 (en) | 2004-11-16 | 2006-10-19 | Avidia Research Institute | Protein scaffolds and uses thereof |
NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
US7968091B2 (en) | 2005-02-16 | 2011-06-28 | The General Hospital Corporation | Methods and compositions to regulate iron metabolism |
EP1884235A1 (en) | 2005-04-26 | 2008-02-06 | Ajinomoto Co., Inc. | Myeloerythroid progenitor differentiation inducer |
JP2007099764A (ja) | 2005-09-09 | 2007-04-19 | Ajinomoto Co Inc | 血糖低下剤 |
CA2621623A1 (en) | 2005-09-28 | 2007-04-05 | Zymogenetics, Inc. | Il-17a and il-17f antagonists and methods of using the same |
US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
CN104844713B (zh) | 2005-11-23 | 2021-05-14 | 阿塞勒隆制药公司 | Activin-ActRIIa拮抗剂及其促进骨骼生长的应用 |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
JP2009518422A (ja) | 2005-12-06 | 2009-05-07 | アムジェン インコーポレイテッド | ミオスタチン・アンタゴニストの使用 |
CA2632936A1 (en) | 2005-12-20 | 2007-06-28 | Merck Frosst Canada Ltd. | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
US20070161578A1 (en) | 2005-12-21 | 2007-07-12 | Hwa Joyce J | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist |
WO2007076127A2 (en) | 2005-12-22 | 2007-07-05 | Biogen Idec Ma Inc | Condensed imidazoles or pyrazoles and their use as transforming growth factor modulators |
US7361510B2 (en) | 2006-01-20 | 2008-04-22 | Beckman Coulter, Inc. | Methods of detection of iron deficiency |
EP1976377A4 (en) | 2006-01-25 | 2010-06-23 | Wellstat Therapeutics Corp | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS |
ATE530066T1 (de) | 2006-02-28 | 2011-11-15 | Wellstat Therapeutics Corp | Verbindungen zur behandlung von stoffwechselstörungen |
US8008074B2 (en) | 2006-03-20 | 2011-08-30 | The Uab Research Foundation | Compositions and methods for improving bone mass through modulation of receptors of PTH and fragments thereof |
EP2007813A2 (en) | 2006-04-14 | 2008-12-31 | Amgen Inc. | Agonist erythropoietin receptor antibodies |
WO2007133653A2 (en) | 2006-05-09 | 2007-11-22 | Hemaquest Pharmaceuticals, Inc. | Methods for treating blood disorders |
EP2048948B1 (en) | 2006-07-21 | 2012-02-29 | Lyne Laboratories, Inc. | Liquid compositions of calcium acetate |
GB0615129D0 (en) | 2006-07-29 | 2006-09-06 | Univ Cardiff | Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies |
WO2008030367A2 (en) | 2006-09-01 | 2008-03-13 | The General Hospital Corporation | Selective myostatin inhibitors |
CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
WO2008060139A1 (en) | 2006-11-17 | 2008-05-22 | Erasmus University Medical Center Rotterdam | Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein |
WO2008073292A2 (en) | 2006-12-08 | 2008-06-19 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Method for protecting renal tubular epithelial cells from radiocontrast nephro parhy (rcn) |
EP2103628A4 (en) | 2006-12-14 | 2012-02-22 | Forerunner Pharma Res Co Ltd | MONOCLONAL ANTIBODY ANTI-CLAUDIN 3, AND TREATMENT AND DIAGNOSIS OF CANCER USING SUCH ANTIBODY |
AU2013221910B2 (en) * | 2006-12-18 | 2016-11-17 | Acceleron Pharma Inc. | Activin-ActRII antagonists and uses for increasing red blood cell levels |
US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
BRPI0720476B1 (pt) * | 2006-12-18 | 2022-05-31 | Acceleron Pharma Inc | Uso de um polipeptídeo de actrii para tratar anemia em um paciente humano |
BRPI0806861A2 (pt) | 2007-02-01 | 2014-08-05 | Acceleron Pharma Inc | Antagonistas de ativina-actriia e usos para tratar ou prevenir câncer de mama |
TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
TWI525102B (zh) | 2007-02-09 | 2016-03-11 | 艾瑟勒朗法瑪公司 | 包含ActRIIa-Fc融合蛋白的醫藥組合物;ActRIIa-Fc融合蛋白於治療或預防與癌症相關的骨質流失之用途;ActRIIa-Fc融合蛋白於治療或預防多發性骨髓瘤之用途 |
TW201718635A (zh) | 2007-03-06 | 2017-06-01 | 安美基公司 | 變異之活動素受體多肽及其用途 |
EP2150560A1 (en) | 2007-06-01 | 2010-02-10 | Wyeth | Methods and compositions for modulating bmp-10 activity |
WO2009009059A1 (en) | 2007-07-09 | 2009-01-15 | Biogen Idec Ma Inc. | Spiro compounds as antagonists of tgf-beta |
JP2010535708A (ja) | 2007-08-03 | 2010-11-25 | ビオマリン アイジーエー リミテッド | デュシェンヌ型筋ジストロフィーの治療のための薬物併用 |
GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
GB0715938D0 (en) | 2007-08-15 | 2007-09-26 | Vastox Plc | Method of treatment of duchenne muscular dystrophy |
WO2009025651A1 (en) | 2007-08-17 | 2009-02-26 | University Of Maine System Board Of Trustees | Biologically active peptide and method of using the same |
CN103877564A (zh) | 2007-09-18 | 2014-06-25 | 阿塞勒隆制药公司 | 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途 |
PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
WO2009070243A2 (en) | 2007-11-21 | 2009-06-04 | Amgen Inc. | Wise binding agents and epitopes |
JP5638961B2 (ja) | 2008-03-13 | 2014-12-10 | ザ ジェネラル ホスピタル コーポレイション | Bmpシグナル伝達経路のインヒビター |
WO2009137075A1 (en) | 2008-05-06 | 2009-11-12 | Acceleron Pharma Inc. | Anti-activin antibodies and uses for promoting bone growth |
WO2009137613A2 (en) | 2008-05-06 | 2009-11-12 | Joslin Diabetes Center, Inc. | Methods and compositions for inducing brown adipogenesis |
DK2318028T3 (da) | 2008-06-26 | 2020-05-04 | Acceleron Pharma Inc | Antagonister af opløselig activin-aktriia og anvendelser til øgning af røde blodcelleniveauer |
US20100015144A1 (en) | 2008-06-26 | 2010-01-21 | Acceleron Pharma Inc. | Methods for dosing an activin-actriia antagonist and monitoring of treated patients |
US8637611B2 (en) | 2008-08-13 | 2014-01-28 | Designer Molecules, Inc. | Amide-extended crosslinking compounds and methods for use thereof |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
TWI784538B (zh) | 2008-08-14 | 2022-11-21 | 美商艾瑟勒朗法瑪公司 | 使用gdf阱以增加紅血球水平 |
WO2010083034A1 (en) | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
CA2750559A1 (en) | 2009-02-05 | 2010-08-12 | Digna Biotech, S.L. | Pharmaceutical formulations of tgf-.beta.1 inhibitor peptides |
NO2424895T3 (hr) | 2009-04-27 | 2018-02-03 | ||
CN102482339B (zh) | 2009-06-08 | 2015-06-17 | 阿塞勒隆制药公司 | 用于增加产热脂肪细胞的方法 |
KR20180026795A (ko) | 2009-06-12 | 2018-03-13 | 악셀레론 파마 인코포레이티드 | 절두된 ActRIIB-FC 융합 단백질 |
EP3838919A1 (en) * | 2009-08-13 | 2021-06-23 | Acceleron Pharma Inc. | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels |
CA2773494A1 (en) | 2009-09-09 | 2011-03-17 | Acceleron Pharma Inc. | Actriib antagonists and dosing and uses thereof |
JP5836961B2 (ja) | 2009-11-03 | 2015-12-24 | アクセルロン ファーマ, インコーポレイテッド | 脂肪肝疾患を処置するための方法 |
ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
WO2012027065A2 (en) | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
JP6472999B2 (ja) | 2011-07-01 | 2019-02-20 | ノバルティス アーゲー | 代謝障害を治療するための方法 |
EP3875104A1 (en) | 2011-10-17 | 2021-09-08 | Acceleron Pharma Inc. | Compositions for treating myelofibrosis |
KR102143476B1 (ko) | 2012-07-02 | 2020-08-12 | 쿄와 기린 가부시키가이샤 | 항bmp9 항체를 유효 성분으로 하는, 신장성 빈혈, 암성 빈혈 등의 빈혈에 대한 치료제 |
ES2753811T3 (es) | 2012-10-24 | 2020-04-14 | Celgene Corp | Biomarcador para uso en el tratamiento de anemia |
EP3527219A1 (en) | 2012-10-24 | 2019-08-21 | Celgene Corporation | Methods for treating anemia |
EP3964224A1 (en) | 2012-11-02 | 2022-03-09 | Celgene Corporation | Activin-actrii antagonists and uses for use in treating renal disease |
MA39722A (fr) | 2014-03-21 | 2021-06-02 | Acceleron Pharma Inc | Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11 |
MX2016013635A (es) | 2014-04-18 | 2017-02-02 | Acceleron Pharma Inc | Métodos para aumentar los niveles de eritrocitos y tratar de la enfermedad de células falciformes. |
BR122023023170A2 (pt) | 2014-06-13 | 2024-02-20 | Acceleron Pharma Inc. | Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia |
MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
ES2946160T3 (es) | 2014-12-03 | 2023-07-13 | Celgene Corp | Antagonistas de activina-ActRII y usos para tratar síndrome mielodisplásico |
MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
CN107847562A (zh) | 2015-05-13 | 2018-03-27 | 细胞基因公司 | 使用 ACTRII 配体陷阱治疗 β‑地中海贫血 |
EP4190805A3 (en) | 2015-05-20 | 2023-08-16 | Celgene Corporation | In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps |
WO2017024171A1 (en) | 2015-08-04 | 2017-02-09 | Acceleron Pharma Inc. | Methods for treating myeloproliferative disorders |
WO2017079591A2 (en) | 2015-11-04 | 2017-05-11 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
EP3380121B1 (en) | 2015-11-23 | 2023-12-20 | Acceleron Pharma Inc. | Actrii antagonist for use in treating eye disorders |
PT3496739T (pt) | 2016-07-15 | 2021-06-21 | Acceleron Pharma Inc | Composições compreendendo polipéptidos actriia para uso no tratamento de hipertensão pulmonar |
AU2017302282A1 (en) | 2016-07-27 | 2019-02-07 | Acceleron Pharma Inc. | Methods and compositions for treating myelofibrosis |
BR112019006918A2 (pt) | 2016-10-05 | 2019-06-25 | Acceleron Pharma Inc | proteínas actriib variantes e usos das mesmas |
EP3638243A4 (en) | 2017-06-14 | 2021-03-17 | Celgene Corporation | METHOD OF TREATMENT OF MYELOPROLIFERATIVE NEOPLASM ASSOCIATED MYELOFIBROSIS AND ANEMIA |
JP2022509525A (ja) | 2018-10-31 | 2022-01-20 | セルジーン コーポレイション | 環状鉄芽球が見られる対象における非常に低リスク、低リスクまたは中程度のリスクの骨髄異形成症候群による貧血の、アクチビン-actriiリガンドトラップを用いた治療 |
-
2015
- 2015-12-03 ES ES15865213T patent/ES2946160T3/es active Active
- 2015-12-03 LT LTEPPCT/US2015/063595T patent/LT3227675T/lt unknown
- 2015-12-03 JP JP2017548364A patent/JP2018501307A/ja active Pending
- 2015-12-03 HU HUE15865213A patent/HUE062189T2/hu unknown
- 2015-12-03 SI SI201531946T patent/SI3227675T1/sl unknown
- 2015-12-03 TW TW104140599A patent/TWI730949B/zh active
- 2015-12-03 IL IL252631A patent/IL252631B2/en unknown
- 2015-12-03 CN CN202210225878.XA patent/CN114675039A/zh active Pending
- 2015-12-03 US US15/532,329 patent/US11471510B2/en active Active
- 2015-12-03 HR HRP20230504TT patent/HRP20230504T1/hr unknown
- 2015-12-03 DK DK15865213.1T patent/DK3227675T3/da active
- 2015-12-03 KR KR1020177018131A patent/KR102556991B1/ko active IP Right Grant
- 2015-12-03 EP EP23160992.6A patent/EP4233889A3/en active Pending
- 2015-12-03 PT PT158652131T patent/PT3227675T/pt unknown
- 2015-12-03 WO PCT/US2015/063595 patent/WO2016090077A1/en active Application Filing
- 2015-12-03 CA CA2969572A patent/CA2969572A1/en active Pending
- 2015-12-03 PL PL15865213.1T patent/PL3227675T3/pl unknown
- 2015-12-03 AU AU2015358469A patent/AU2015358469B2/en active Active
- 2015-12-03 TW TW110103864A patent/TWI773117B/zh active
- 2015-12-03 EP EP15865213.1A patent/EP3227675B1/en active Active
- 2015-12-03 FI FIEP15865213.1T patent/FI3227675T3/fi active
- 2015-12-03 RS RS20230392A patent/RS64214B1/sr unknown
- 2015-12-03 BR BR112017011722A patent/BR112017011722A2/pt not_active Application Discontinuation
- 2015-12-03 CN CN201580075198.2A patent/CN107533040B/zh active Active
- 2015-12-03 MD MDA20180012A patent/MD4801C1/ro active IP Right Grant
-
2018
- 2018-04-06 HK HK18104547.0A patent/HK1245397A1/zh unknown
- 2018-06-26 HK HK18108223.2A patent/HK1248807A1/zh unknown
-
2020
- 2020-11-20 JP JP2020193117A patent/JP7092853B2/ja active Active
-
2021
- 2021-08-05 AU AU2021212084A patent/AU2021212084B2/en active Active
-
2023
- 2023-06-01 CY CY20231100261T patent/CY1126033T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20230504T1 (hr) | Antagonisti aktivin-actrii i upotreba u liječenju mijelodisplastičnog sindroma | |
JP2020515581A (ja) | T細胞受容体のシグナル伝達を阻害するまたは調節することによってt細胞の疲弊を治療する方法 | |
BR112014026718A2 (pt) | variantes ctla-4 | |
SI2691112T1 (en) | STABILITY FORMULATION PROTITELES FOR HUMAN PROGRAMMED DEPRESSOR RECEPTOR PD-1 AND RELATED HEALTH | |
JP2018505882A5 (hr) | ||
RU2019106804A (ru) | Лечение и устойчивая вирусологическая ремиссия при вич-инфекции у haart-стабилизированных пациентов с помощью антител против cd4 | |
RU2015116264A (ru) | Композиции и способы лечения сердечной недостаточности у пациентов с диабетом | |
RU2015104001A (ru) | Комбинированная терапия для лечения глиобластомы | |
WO2022150732A3 (en) | Chimeric receptor therapy | |
JP2021517144A (ja) | Cd47遮断療法およびcd38抗体の組み合わせ | |
Li et al. | Efficacy of low-dose rituximab in combination with recombinant human thrombopoietin in treating ITP | |
Nakamoto et al. | Effects of sustained‐release beraprost in patients with primary glomerular disease or nephrosclerosis: CASSIOPEIR study results | |
RU2016129911A (ru) | Слитые белки, содержащие фактор ix, для профилактического лечения больных гемофилией и способы его осуществления | |
Oh et al. | Safety and efficacy of conversion from twice-daily tacrolimus to once-daily tacrolimus one month after transplantation: randomized controlled trial in adult renal transplantation | |
BR112021022503A2 (pt) | Métodos de administração de anticorpo anti-cd38 para tratar mieloma múltiplo | |
HRP20231229T1 (hr) | Paradigma liječenja za protutijelo anti-cd19 i venetoklaks kombinacijsko liječenje | |
BR112017014847A2 (pt) | "método para tratar anemia com o uso de formulação de epo de atuação prolongada" | |
Nilsson | The management of hemophilia patients with inhibitors | |
Scully et al. | Pharmacodynamic profile of a recombinant ADAMTS13 (BAX930) in hereditary thrombotic thrombocytopenic purpura (Upshaw-Schulman Syndrome (USS)) | |
Cho et al. | Effect of pretreatment with palonosetron on withdrawal movement associated with rocuronium injection | |
Christopoulou et al. | P116 ATHENA (GOG-3020/ENGOT-ov45; EudraCT 2017–004557–17; NCT03522246): A randomised, double-blind, placebo-controlled, phase 3 study of the poly (ADP-Ribose) polymerase (PARP) inhibitor rucaparib+ the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer (OC) | |
Wood et al. | Rituximab | |
Wang et al. | Agonistic Death Receptor 5 (DR5) IgM antibody IGM-8444 induces tumor cell apoptosis in vitro and in vivo and has a favorable in vitro safety profile | |
Hunter | Xylocaine | |
Mukhopadhyay et al. | Olanzapine, an effective and affordable adjuvant in prophylaxis for chemotherapy induced nausea and vomiting on platinum based chemotherapy patients |